It's Crunch Time for Biotech Companies
604932
Washington area biotech companies will face pivotal moments this year, finding out whether key products work before money dries up, fending off competition from bigger companies,  and, perhaps filing to go public.-The Washington Post
443190
A conglomerate of Japanese companies hopes to develop biochips.
496783
Here are a few companies primed for growth.
285697
Looking at drug R&D is the best way to begin assessing biotech companies.
731230
The biotech mines extra value from its compound library.
426295
Before Christophe Echeverri decided to spin his postdoctoral project into a biotech company called Cenix BioScience in 1999, he hesitated, fearing the switch from lab coat to business suit was a "move over to ...
480772
Biotech company buys itself a bigger future.
5834
Nurtured by billions of dollars in government grants and venture investments, nanotechnology companies are getting ready to go public.
357723
Boston officials are considering plans to invest city funds directly into biotechnology companies, part of a broader effort to stimulate the hot industry within city limits and create jobs.
709018
A new strategy aiming to attract global investment in the field of life sciences is launched.
148619
China's biotech sector accounts for just a sliver of its pharmaceutical industry and operates under the cloud of a massive review of licenses issued under a regulator executed last year for accepting bribes.
472251
In biotech investing, it pays to close your ears to all the hubbub.
503373
This season's flu-shot shortage is enticing companies to enter a market that others have largely abandoned because of poor profits.
172265
Charly Travers offers advice on withstanding the volatility of the biotech sector.
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
632263
Late-stage drugs are crucial for a company beset with patent losses.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.